Skip to content

Düsseldorf Bread Study

Düsseldorf Bread Study on Health Effects of Bread.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04248673
Acronym
DBS
Enrollment
80
Registered
2020-01-30
Start date
2020-08-01
Completion date
2021-10-21
Last updated
2021-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Weight

Brief summary

The hypothesis is to be tested that eating carbohydrate-reduced bread over three months leads to a significant weight difference compared to conventional, carbohydrate-rich bread.

Detailed description

Carbohydrate reduction is an important element for weight loss or can also be used to keep weight constant. Since the majority of the carbohydrates consumed daily in industrialized countries come from bread and rolls, the present study will examine the effect of two different types of bread on the weight development of overweight bread consumers. The two types of bread differ in their carbohydrate content and the hypothesis is to be tested that eating carbohydrate-reduced bread over three months leads to a significant weight difference compared to conventional, carbohydrate-rich bread. The comparison of the two types of bread is carried out triple blinded. During two visits (before and after the bread consumption phase), the health status is determined with physical parameters and laboratory parameters from a blood test. The primary endpoint is body weight. Overall, this study will for the first time allow extensive statements to be made on the health value of the three-month consumption of two different types of bread.

Interventions

OTHERcarbohydrate reduced bread

Consumption of carbohydrate reduced bread for three months.

OTHERcarbohydrate rich bread

Consumption of carbohydrate rich bread for three months.

Sponsors

Bakery Hinkel
CollaboratorUNKNOWN
West German Center of Diabetes and Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
Yes

Inclusion criteria

\- body mass index of at least 27 kg/m2

Exclusion criteria

* serious illness with hospitalization in the last 3 months * Changes in body weight (estimated weekly average) by more than 2 kg in the past 4 weeks * Non-smoking status for less than 3 months * Change of smoking habits planned during the study * acute diseases such as respiratory or gastrointestinal infections * Chronic diseases, e.g. Tumor diseases, chronic obstructive pulmonary disease (COPD), asthma, dementia, intestinal diseases, diabetes * regular use of medication (except contraceptives) such as Lipid lowering, blood pressure lowering, weight-regulating medication, aspirin * no contraception in women of childbearing age or breastfeeding a child * high sporting activity (≥ 1 hour per day) * planned absence of\> 7 days during the intervention phase

Design outcomes

Primary

MeasureTime frameDescription
body weight3 monthschange of body weight in kg

Secondary

MeasureTime frameDescription
triglycerides3 monthschange of triglycerides in mg/dl
total cholesterol3 monthschange of total cholesterol in mg/dl
hip circumference3 monthschange of hip circumference in cm
body mass index3 monthschange of body mass index in kg/m\*m (body weight and height will be combined to report body mass index)
waist circumference3 monthschange of weight circumference in cm
waist-to-height-index3 monthschange of waist-to-height-index (waist circumference and height will be combined to report waist-to-height-index)
high-density lipoprotein (HDL) cholesterol3 monthschange of high-density lipoprotein (HDL) cholesterol in mg/dl
low-density lipoprotein (HDL) cholesterol3 monthschange of low-density lipoprotein (HDL) cholesterol in mg/dl
hemoglobin A1c (HbA1C)3 monthschange of hemoglobin A1c (HbA1C) in %
fasting blood glucose3 monthschange of fasting blood glucose in mg/dl
fasting blood insulin3 monthschange of fasting blood insulin µU/ml
homeostasis model assessment of insulin resistance (HOMA-IR)3 monthschange of homeostasis model assessment of insulin resistance (HOMA-IR) (fasting blood glucose and fasting blood insulin will be combined to report HOMA-IR)
blood pressure3 monthschange of blood pressure in mmHg
heightat baselineheight in cm

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026